系統性硬化病RNP抗體的臨床意義_《華西醫學》

作者：

四川大學華西醫院風濕免疫科,四川成都 610041;

關鍵詞：

硬皮病 RNP抗體 ENA抗體

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的:分析并探討RNP抗體在系統性硬化病中的臨床意義。方法:收集自2004年以來在我院做過皮膚活檢,并通過病理和臨床確診為系統性硬化病的62例住院患者。分為RNP+組(20例),SCL-70+組(20例),ENA-組(22例)。結果:RNP+組較其它兩組關節痛、雷諾現象發生率明顯升高(P lt;0.05),肌炎發生率亦有升高,指端病變發生率明顯降低(P lt;0.05)。結論:通過對系統性硬化病患者體內部分典型抗體的研究,有利于臨床醫生判斷不同抗體陽性的系統性硬化瘤患者病情的嚴重程度和預后。

引用本文： 葉楊,李敏,石連杰,趙臻怡,鐘雪,陳清容,謝一舟,楊南萍. 系統性硬化病RNP抗體的臨床意義. 華西醫學, 2009, 24(8): 2070-2072. doi: 復制

1.	葉任高.內科學[M].第6版,北京:人民衛生出版社,2004:933-933..
2.	MASI A T, RODNAN G P, MEDESGER T A. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee[J]. Arthritis Rheum,1980,23(5):581-590.
3.	STEEN V D, MEDSGER TA J R, RODNAN G P. DPenicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis[J]. Ann Intern Med,1982,97(5):652-659.
4.	JACOBSEN S, HALBERG P, ULLMAN S. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis[J]. Br J Rheumatol,1998,37(1):39-45.
5.	IHN H, YAMANE K, YAZAWA N. Distribution and antigen specificity of antiU1RNP antibodies in patients with systemic sclerosis[J]. Clin Exp Immunol,1999,117(2):383-387.
6.	OKANO Y, STEEN V D, MEDSGER T A. Autoantibody to U3 nuclerolar ribonucleoprotein(fibrillarin) in patients with systemic sclerosis[J]. Arthritis Rheum,1992,35(1):95-100.
7.	JACOBSEN S, ULLMAN S, SHEN G Q. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with sclerosis[J]. J Rheumatol,2001,28(11):2454-2459.

1. 葉任高.內科學[M].第6版,北京:人民衛生出版社,2004:933-933..
2. MASI A T, RODNAN G P, MEDESGER T A. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee[J]. Arthritis Rheum,1980,23(5):581-590.
3. STEEN V D, MEDSGER TA J R, RODNAN G P. DPenicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis[J]. Ann Intern Med,1982,97(5):652-659.
4. JACOBSEN S, HALBERG P, ULLMAN S. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis[J]. Br J Rheumatol,1998,37(1):39-45.
5. IHN H, YAMANE K, YAZAWA N. Distribution and antigen specificity of antiU1RNP antibodies in patients with systemic sclerosis[J]. Clin Exp Immunol,1999,117(2):383-387.
6. OKANO Y, STEEN V D, MEDSGER T A. Autoantibody to U3 nuclerolar ribonucleoprotein(fibrillarin) in patients with systemic sclerosis[J]. Arthritis Rheum,1992,35(1):95-100.
7. JACOBSEN S, ULLMAN S, SHEN G Q. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with sclerosis[J]. J Rheumatol,2001,28(11):2454-2459.

《華西醫學》

系統性硬化病RNP抗體的臨床意義

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《華西醫學》

系統性硬化病RNP抗體的臨床意義

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料